Overview

Emerging prenatal therapies for cystic fibrosis are showing promise for improving neonatal outcomes when initiated earlier in pregnancy. But early intervention requires early detection. ‍

Recently published in the peer-reviewed Journal of Cystic Fibrosis, our latest research demonstrates how UNITY Fetal Risk™ Screen enables timely detection of CF-affected pregnancies, opening the door for potential therapeutic intervention in hopes of improving outcomes.

Watch our webinar recording to explore the findings and connect directly with the study authors.

What You’ll Learn

• How routine cell-free DNA (cfDNA) prenatal screening can identify pregnancies at elevated risk for cystic fibrosis (CF), including how UNITY screening works and where it fits in the prenatal landscape.
• The clinical pathway from carrier identification to prenatal CF diagnosis, and how early detection enables timely evaluation for emerging in utero CFTR modulator therapies.
• Current evidence and expert perspectives on prenatal CF treatment, including eligibility criteria, timing, expected benefits, and ongoing research efforts.
• Real-world case discussions that show how screening results, genetic counseling, and therapy considerations guide clinical decision making for families.